Discriminating Between Bipolar Disorder and Major Depressive Disorder

Psychiatric Clinics of North America

Volumn 39, Issue 1, 2016, Pages 1-10

  Vöhringer, Paul A ^a,b   Perlis, Roy H ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHILE   (Chile)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bipolar disorder; Diagnosis; Irritability; Major depressive disorder; Misdiagnosis; Nosology

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; LITHIUM CARBONATE; PLACEBO;

BIPOLAR DISORDER; DIAGNOSTIC ERROR; DISEASE SEVERITY; DRUG EFFICACY; DSM-5; HIGH RISK PATIENT; HUMAN; MAJOR DEPRESSION; MANIA; MONOTHERAPY; MOTIVATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELIABILITY; REMISSION; REVIEW; RISK ASSESSMENT; SEX RATIO; SYMPTOMATOLOGY; DEPRESSIVE DISORDER, MAJOR; DIFFERENTIAL DIAGNOSIS;

BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DIFFERENTIAL; HUMANS;

EID: 84957797055     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2015.10.001     Document Type: Review

References (53)

1. Goodwin F.K., Jamison K.R. Manic-depressive illness: bipolar disorders and recurrent depression 2007, Oxford Ed, Oxford (United Kingdom). 2nd edition.
2. American Psychiatric Association DSM-5-Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Association, Washington, DC. 5th edition.
3. Ghaemi S.N., Hsu D.J., Soldani F., et al. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003, 5(6):421-433. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/14636365.
4. Ghaemi S.N., Ostacher M.M., El-Mallakh R.S., et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010, 71(4):372-380.
5. Yatham L.N., Vieta E., Goodwin G.M., Agomelatine Study Group, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry 2015, [Epub ahead of print].
6. Ghaemi SN, Vöhringer PA, Patkar A, et al. Citalopram for acute and preventive efficacy in bipolar depression (CAPE-BD): a double-blind randomized, placebo-controlled trial. Am J Psychiatry, in press.
7. McGirr A, Vöhringer PA, Ghaemi SN, et al. The safety and efficacy of adjunctive modern antidepressant therapy with a mood stabilizer or antipsychotic in acute bipolar depression: a meta-analysis of randomized placebo controlled trials. Am J Psychiatry, in press.
8. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163(11):1905-1917.
9. Kirsch I., Deacon B.J., Huedo-Medina T.B., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5(2):e45.
10. Vohringer P.A., Ghaemi S.N. Solving the antidepressant efficacy question: effect sizes in major depressive disorder. Clin Ther 2011, 33(12):B49-B61.
11. Perlis R.H., Uher R., Ostacher M., et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry 2011, 68(4):351-360.
12. Akiskal H.S. Validating 'hard' and 'soft' phenotypes within the bipolar spectrum: continuity or discontinuity?. J Affect Disord 2003, 73(1-2):1-5. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/12507732.
13. Sachs G.S., Nierenberg A.A., Calabrese J.R., et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007, 356(17):1711-1722.
14. Koukopoulos A., Sani G. DSM-criteria for depression with mixed features: a farewell to mixed depression. Acta Psychiatr Scand 2014, 129(1):4-16.
15. Sani G., Napoletano F., Vohringer P.A., et al. Mixed depression: clinical features and predictors of its onset associated with antidepressant use. Psychother Psychosom 2014, 83(4):213-221.
16. Murray M.L., Thompson M., Santosh P.J., et al. Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf 2005, 28(12):1151-1157. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/16329717.
17. van Praag H.M. Why has the antidepressant era not shown a significant drop in suicide rates?. Crisis 2002, 23(2):77-82.
18. Perlis R.H. Misdiagnosis of bipolar disorder. Am J Manag Care 2005, 11(Suppl):S271-S274. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/16232009.
19. Ruggero C.J., Zimmerman M., Chelminski I., et al. Borderline personality disorder and the misdiagnosis of bipolar disorder. J Psychiatr Res 2010, 44(6):405-408.
20. Ghaemi S.N., Ko J.Y., Goodwin F.K. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002, 47(2):125-134. Available at:. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11926074.
21. Benazzi F. Underdiagnosis of bipolar II disorders in the community. J Clin Psychiatry 2003, 64(9):1130-1131. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/14628991.
22. Smith D.J., Ghaemi N. Is underdiagnosis the main pitfall when diagnosing bipolar disorder? Yes. BMJ 2010, 340:c854.
23. Berk M., Dodd S. Bipolar II disorder: a review. Bipolar Disord 2005, 7(1):11-21.
24. Swartz H.A., Frank E., Cheng Y. A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression. Bipolar Disord 2012, 14(2):211-216.
25. Benazzi F., Akiskal H.S. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J Affect Disord 2003, 73(1-2):33-38. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/12507735.
26. Perlis R.H., Miyahara S., Marangell L.B., STEP-BD Investigators, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004, 55(9):875-881.
27. Gunderson J.G., Weinberg I., Daversa M.T., et al. Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. Am J Psychiatry 2006, 163(7):1173-1178.
28. Berk M., Dodd S., Berk L. The management of bipolar disorder in primary care: a review of existing and emerging therapies. Psychiatry Clin Neurosci 2005, 59(3):229-239.
29. Pavlova B., Perlis R.H., Alda M., et al. Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry 2015, 2(8):710-717.
30. Barroilhet S., Vohringer P.A., Ghaemi S.N. Borderline versus bipolar: differences matter. Acta Psychiatr Scand 2013, 128(5):385-386.
31. Trede K., Salvatore P., Baethge C., et al. Manic-depressive illness: evolution in Kraepelin's Textbook, 1883-1926. Harv Rev Psychiatry 2005, 13(3):155-178.
32. Swann A.C., Geller B., Post R.M., et al. Practical clues to early recognition of bipolar disorder: a primary care approach. Prim Care Companion J Clin Psychiatry 2005, 7(1):15-21. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/15841189.
33. Angst J., Gamma A., Benazzi F., et al. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord 2003, 73(1-2):133-146. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/12507746.
34. Benazzi F. Chronic atypical major depressive episode in private practice: unipolar and bipolar II. Acta Psychiatr Scand 1999, 100(6):418-423. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/10626919.
35. Hantouche E.G., Akiskal H.S. Bipolar II vs. unipolar depression: psychopathologic differentiation by dimensional measures. J Affect Disord 2005, 84(2-3):127-132.
36. Moreno C., Laje G., Blanco C., et al. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007, 64(9):1032-1039.
37. Perlis R.H., Brown E., Baker R.W., et al. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am J Psychiatry 2006, 163(2):225-231.
38. Kessler R.C., Berglund P., Demler O., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):593-602.
39. Kessler R.C., Berglund P., Demler O., National Comorbidity Survey Replication, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289(23):3095-3105.
40. Merikangas K.R., Jin R., He J.P., et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011, 68(3):241-251.
41. Hendrick V., Altshuler L.L., Gitlin M.J., et al. Gender and bipolar illness. J Clin Psychiatry 2000, 61(5):393-396. [quiz: 397]. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/10847318.
42. Jones I., Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry 2005, 186:453-454.
43. Mitchell P.B., Frankland A., Hadzi-Pavlovic D., et al. Comparison of depressive episodes in bipolar disorder and in major depressive disorder within bipolar disorder pedigrees. Br J Psychiatry 2011, 199(4):303-309.
44. Perlis R.H., Smoller J.W., Fava M., et al. The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. J Affect Disord 2004, 79(1-3):291-295.
45. Benazzi F. Bipolar II disorder and major depressive disorder: continuity or discontinuity?. World J Biol Psychiatry 2003, 4(4):166-171. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/14608587.
46. Perlis R.H. The emerging genetics of bipolar disorder. The bipolar book: history, neurobiology, and treatment 2015, 181-190. Oxford University Press, New York. A. Yildiz, P. Ruiz (Eds.).
47. Perlis R.H. Translating biomarkers to clinical practice. Mol Psychiatry 2011, 16(11):1076-1087.
48. Chen J.J., Zhou C.J., Lui Z., et al. Divergent urinary metabolic phenotypes between major depressive disorder and bipolar disorder identified by a combined GC-MS and NMR spectroscopic metabonomic approach. J Proteome Res 2015, 14(8):3382-3389.
49. Munkholm K., Peijs L., Vinberg M., et al. A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder. Transl Psychiatry 2015, 4(5):614.
50. Wolfers T., Buitelaar J.K., Beckmann C.F., et al. From estimating activation locality to predicting disorder: a review of pattern recognition for neuroimaging-based psychiatric diagnostics. Neurosci Biobehav Rev 2015, 57:328-349.
51. Goldberg J.F., Harrow M. A 15-year prospective follow-up of bipolar affective disorders: comparisons with unipolar nonpsychotic depression. Bipolar Disord 2011, 13(2):155-163.
52. Prieto M.L., Youngstrom E.A., Ozerdem A., et al. Different patterns of manic/hypomanic symptoms in depression: a pilot modification of the hypomania checklist-32 to assess mixed depression. J Affect Disord 2014, 172C:355-360.
53. Zimmerman M., Chelminski I., Young D., et al. A clinically useful self-report measure of the DSM-mixed features specified of major depressive disorder. J Affect Disord 2014, 168:357-362.